Skip to content

Research at St Andrews

Phenotypic resistance in mycobacteria: is it because I am old or fat that I resist you?

Research output: Contribution to journalArticle

DOI

Open Access permissions

Open

Author(s)

Robert J H Hammond, Vincent O Baron, Katarina Oravcova, Sam Lipworth, Stephen H Gillespie

School/Research organisations

Abstract

Synopsis
Objectives
We aimed to explore the phenomenon of phenotypic resistance to anti-mycobacterial antibiotics and to determine whether this was associated with cell age or presence of lipid bodies.

Methods
The accumulation of lipid body positive cells (lipid rich- LR) was followed using cell staining and flow cytometry. LR cells of M. smegmatis, M. marinum, M. fortuitum and BGC were separated from non-lipid body containing cells (lipid poor- LP) and their MBC determined. We also compared the MBC of LR and LP from “old” and “young” cultures.


Results
The LR cells of all species were more resistant to antibiotics than LP cells. For Mycobacterium bovis (BCG) the susceptibility ratios were as follows; Rifampicin-5X, isoniazid-16.7X, ethambutol-5X, ciprofloxacin-5X. Phenotypic resistance was found in LR cells irrespective of cell age.

Conclusions
We have shown that phenotypic antibiotic resistance is associated with the presence of lipid bodies irrespective of cell age. These data have important implications for our understanding of relapse in mycobacterial infections.

Close

Details

Original languageEnglish
JournalJournal of Antimicrobial Chemotherapy
VolumeAdvance Access
DOIs
StatePublished - 9 Jul 2015

    Research areas

  • Mycobacterium tuberculosis, Antibiotic resistance, Lipid rich, Lipid poor

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

    Tweed, C. D., Crook, A. M., Amukoye, E. I., Dawson, R., Diacon, A. H., Hanekom, M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murphy, M. E., Murthy, S. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M., Wills, G. H. & Gillespie, S. H. 11 Jul 2018 In : BMC Infectious Diseases. 18, 11 p., 317

    Research output: Contribution to journalArticle

  2. Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: in the Cornell mouse model

    Liu, Y., Pertinez, H., Davies, G. R., Gillespie, S. H., Coates, A. R. & Hu, Y. Jul 2018 In : Antimicrobial Agents and Chemotherapy. 62, 7, 9 p., e00190-18

    Research output: Contribution to journalArticle

  3. Forecasting clinical dose-response from pre-clinical studies in tuberculosis research - translational predictions with rifampicin

    Wicha, S. G., Clewe, O., Svensson, R. J., Gillespie, S. H., Hu, Y., Coates, A. R. & Simonsson, U. S. 19 Jun 2018 In : Clinical Pharmacology & Therapeutics. Early View

    Research output: Contribution to journalArticle

  4. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis

    Svensson, E. M., Svensson, R. J., Te Brake, L. H. M., Boeree, M. J., Heinrich, N., Konsten, S., Churchyard, G., Dawson, R., Diacon, A. H., Kibiki, G. S., Minja, L. T., Ntingiya, N. E., Sanne, I., Gillespie, S. H., Hoelscher, M., Phillips, P. P. J., Simonsson, U. S. H. & Aarnoutse, R. 18 Jun 2018 In : Clinical Infectious Diseases. 67, 1, p. 34-41 8 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation

    Millard, J., Pertinez, H., Bonnett, L., Model, E. M., Dartois, V., Johnson, J. L., Caws, M., Tiberi, S., Bolhuis, M., Alffenaar, J-W. C., Davies, G. & Sloan, D. J. 23 Mar 2018 In : Journal of Antimicrobial Chemotherapy. 73, 7, p. 1755-1762 8 p.

    Research output: Contribution to journalArticle

  2. Has primary care antimicrobial use really been increasing? Comparison of changes in different prescribing measures for a complete geographic population 1995–2014

    Neilly, M. D. J., Guthrie, B., Hernandez Santiago, V., Vadiveloo, T., Donnan, P. T. & Marwick, C. A. 1 Oct 2017 In : Journal of Antimicrobial Chemotherapy. 72, 10, p. 2921-2930 10 p.

    Research output: Contribution to journalArticle

  3. Improved power for TB phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods

    Svensson, R. J., Gillespie, S. H. & Simonsson, U. S. H. 1 Aug 2017 In : Journal of Antimicrobial Chemotherapy. 72, 8, p. 2311-2319 9 p.

    Research output: Contribution to journalArticle

  4. ST3268: a geographically widespread primate MRSA clone

    Hsu, L-Y., Holden, M. T. G., Koh, T. H., Pettigrew, K. A., Cao, D., Hon, P. Y., Sergio, D. M., Pena, E. & Ogden, B. E. 1 Aug 2017 In : Journal of Antimicrobial Chemotherapy. 72, 8, p. 2401-2403 2 p.

    Research output: Contribution to journalLetter

  5. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients

    Heinrich, N., Dawson, R., du Bois, J., Narunsky, K., Horwith, G., Phipps, A. J., Nacy, C. A., Aarnoutse, R. E., Boeree, M. J., Gillespie, S. H., Venter, A., Henne, S., Rachow, A., Phillips, P. P. J., Hoelscher, M., Diacon, A. H. & on behalf of the Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) 27 Jan 2015 In : Journal of Antimicrobial Chemotherapy.

    Research output: Contribution to journalArticle

ID: 194099904